Improved R&D models, supported by appropriate regulatory pathways, are needed to provide new drugs with greater efficiency, in a framework that is financially viable for all stakeholders. Here, we present the perspective of the European Federation of Pharmaceutical Industries and Associations on the key areas on which to focus to achieve this.
- Susan R. Forda
- Richard Bergström
- Peter Høngaard Andersen
